a Barcelona Clínic Schizophrenia Unit , Neuroscience Institute, Hospital Clínic of Barcelona , Barcelona , Spain.
b Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM) , Barcelona , Spain.
Expert Opin Pharmacother. 2018 Oct;19(14):1623-1629. doi: 10.1080/14656566.2018.1515915. Epub 2018 Sep 24.
A three-month injection of paliperidone palmitate (PP3M) has been gradually introduced in the market since 2015. Recently, and due to different reasons, there is an increase in the LAIAs prescription rates, including patients in early phases of psychotic disorders. Areas covered: The following article provides an overview of the antipsychotic market before providing the reader with an overview of the efficacy and tolerability data of the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. The authors take into account the current state of knowledge, as well as the needs not covered by other therapeutic tools at our disposal at this time. Expert opinion: PP3M offers a substantially longer dosing interval than other options, which may be a potential advancement to reduce nonadherence in some patients. Future research, both from randomized controlled trials and large pragmatic studies in real-world settings, will identify which subpopulation and disease stages may obtain greater benefit from this new formulation.
棕榈酸帕利哌酮 3 个月注射液（PP3M）自 2015 年起逐渐在市场上推出。最近，由于不同的原因，包括处于精神病早期阶段的患者，长效抗精神病药物（LAIAs）的处方率有所增加。
本文首先概述抗精神病药物市场，然后为读者提供 3 个月棕榈酸帕利哌酮治疗精神分裂症的疗效和耐受性数据概述。作者考虑了当前的知识状况，以及目前我们可利用的其他治疗工具尚未涵盖的需求。
PP3M 的给药间隔时间明显长于其他选择，这可能是减少某些患者不依从性的潜在优势。未来的研究，包括随机对照试验和真实世界环境中的大型实用研究，将确定哪些亚人群和疾病阶段可能从这种新制剂中获得更大的益处。
